Biogen Inc. (BIIB) stock price, news and key stats

Price

Last close as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$216.17

Open

$216.41

Day range

$214.81 – $218.29

Volume

606K

About Biogen Inc.

Latest BIIB news

• Steady stream of crossover rounds stock biotech’s IPO pipeline
  IPO & M&A · Sep 9, 2026

  The biotechnology sector is experiencing a resurgence in initial public offerings (IPOs), driven by a steady influx of crossover funding rounds that have bolstered investor confidence. In recent months, public investors have shown renewed interest in biotech firms, paving the way for a series of anticipated public debuts. This renewed enthusiasm is reflected in the increasing number of companies successfully securing crossover investments, which typically involve both private and public investors, thereby enhancing their market readiness. The implications for the market are significant, as a robust IPO pipeline can attract further investment into the biotech sector, potentially leading to a more favorable environment for innovation and development. As companies prepare for their public offerings, the influx of capital from crossover rounds not only strengthens their financial positions but also signals to other investors that there is a viable path to profitability in the sector. This trend may encourage additional firms to pursue IPOs, further stimulating market activity and possibly leading to a competitive landscape that benefits both investors and consumers through accelerated advancements in biotechnology.

• Enhanced FDA-SEC Collaboration: How Life Sciences Companies Think About Disclosure, Insider Trading, and Prediction Markets
  Financial Regulation · Sep 8, 2026

  On August 31, 2026, the U.S. Securities and Exchange Commission (SEC) and the Food and Drug Administration (FDA) announced a new Memorandum of Understanding (MOU) aimed at enhancing collaboration between the two agencies. This initiative is expected to significantly impact how life sciences companies approach disclosure practices, insider trading, and prediction markets. By fostering a more integrated regulatory environment, the agencies aim to improve the transparency and accuracy of information provided to investors regarding drug approvals and clinical trial results. The MOU signals a proactive stance by regulators to address the complexities of the life sciences sector, where timely and accurate disclosures are critical for investor decision-making. As the FDA continues to evaluate new therapies and treatments, the SEC's involvement will likely lead to stricter scrutiny of disclosures related to clinical outcomes and potential market-moving events. This heightened oversight could deter insider trading and promote fairer market practices, as companies will need to ensure compliance with both agencies' standards. Market implications are substantial, as enhanced regulatory scrutiny may lead to increased volatility in life sciences stocks, particularly around key FDA announcements. Companies will need to adopt more rigorous disclosure protocols to mitigate risks associated with non-compliance. Investors should prepare for a landscape where information asymmetry is reduced, potentially leading to more informed trading strategies and a shift in how market participants assess the value of biotech and pharmaceutical firms.

• SEC and FDA sign 3-year market integrity pact
  Financial Regulation · Sep 1, 2026

  The U.S. Securities and Exchange Commission (SEC) and the Food and Drug Administration (FDA) have entered into a three-year agreement aimed at enhancing market integrity, particularly in sectors where financial and health regulations intersect. This unprecedented collaboration seeks to streamline the regulatory process for companies involved in biotechnology and pharmaceuticals, ensuring that financial disclosures align with the safety and efficacy of medical products. Under this pact, the two agencies will share data and insights more effectively, potentially reducing the time it takes for new drugs and therapies to reach the market. This could lead to increased investor confidence in biotech firms, as clearer regulatory pathways may mitigate risks associated with compliance and market volatility. Market analysts predict that this collaboration could stimulate investment in the biotech sector, as firms may find it easier to navigate the complex regulatory landscape. The agreement also underscores the growing recognition of the need for coordinated oversight in an increasingly interconnected financial and healthcare environment. As the SEC and FDA work together, stakeholders will be closely monitoring the implications for market dynamics, particularly how this partnership may influence stock valuations and investment strategies in the life sciences sector.

• SEC, FDA Enter Info-Sharing Pact To Bolster Enforcement
  Financial Regulation · Sep 1, 2026

  The U.S. Securities and Exchange Commission (SEC) and the Food and Drug Administration (FDA) have announced a new information-sharing agreement aimed at enhancing enforcement capabilities across both agencies. This collaboration is designed to improve oversight of companies that operate in both the financial and healthcare sectors, particularly those involved in the development and marketing of pharmaceuticals and medical devices. By sharing data and insights, the agencies hope to better identify potential violations of securities laws and regulations related to misleading claims or fraudulent activities. This partnership comes at a time when regulatory scrutiny is intensifying, particularly in industries where financial and health-related interests intersect. The SEC has been increasingly focused on ensuring that companies provide accurate disclosures about their products and financial health, especially in light of recent high-profile cases of alleged fraud in the biotech sector. The FDA, on the other hand, has been under pressure to ensure that drug and device approvals are not influenced by misleading financial information. Market implications of this agreement could be significant, as companies may face heightened scrutiny regarding their financial disclosures and marketing practices. Investors may need to reassess the risk profiles of firms operating in these dual-regulated spaces, particularly those with a history of aggressive financial reporting or regulatory challenges. Overall, this collaboration signals a proactive approach by U.S. regulators to safeguard both investors and public health.

• Scribe’s early-stage IPO standout defies biotech’s derisking trend
  IPO & M&A · Aug 20, 2026

  Scribe Therapeutics has emerged as a notable exception in the current biotech landscape, where many companies are facing increased scrutiny and derisking amid a challenging market environment. The company is preparing for an early-stage initial public offering (IPO) that has garnered attention due to its innovative approach to chronic cholesterol management. Scribe's treatment leverages epigenetic technology to potentially reduce the adherence burden associated with traditional cholesterol-lowering therapies, while also avoiding the permanent alterations associated with conventional gene editing. The biotech sector has been under pressure as investors become more cautious, often favoring companies with proven track records and established revenue streams. However, Scribe's unique value proposition may resonate with investors looking for breakthrough therapies that address significant unmet medical needs. By focusing on a reversible treatment option, Scribe aims to differentiate itself in a crowded market, which could attract interest from both institutional and retail investors. Market implications of Scribe's IPO could be significant, particularly if the offering is well-received. A successful debut could signal renewed investor confidence in biotech innovation, potentially paving the way for other companies to follow suit. Conversely, if the IPO fails to meet expectations, it may reinforce the prevailing trend of caution in the sector, leading to further derisking and a slowdown in new biotech ventures. As Scribe moves forward, its performance will be closely monitored as a barometer for the broader biotech market's appetite for risk and innovation.

• As China Hunts for Scientific Talent, the US Makes It Easier
  NYT Business · Aug 17, 2026

  In a strategic shift aimed at bolstering its technological and scientific capabilities, the United States has announced measures to simplify the immigration process for foreign talent, particularly in STEM fields. This move comes as China intensifies its efforts to attract top scientists and researchers, creating a competitive landscape for global talent. The U.S. initiative is expected to enhance its appeal to skilled professionals, potentially leading to a significant influx of expertise that could drive innovation and economic growth. The implications for the market are substantial. By streamlining visa processes and providing incentives for foreign researchers, the U.S. aims to secure its position as a leader in technology and innovation. This could result in increased investment in research and development, particularly in sectors such as artificial intelligence, biotechnology, and renewable energy. Conversely, China's aggressive recruitment strategies may lead to a brain drain, as talented individuals weigh their options between the two nations. As both countries vie for supremacy in scientific advancement, the global market may witness shifts in investment patterns and collaborations, influencing various industries and sectors.

• Your Questions Answered: Emerging Trends in Pharma Funding and M&A
  IPO & M&A · Aug 17, 2026

  The pharmaceutical sector is witnessing a significant shift in funding and merger and acquisition (M&A) activity, particularly in the biotech space. Recent trends indicate a robust influx of capital directed toward clinical-stage and platform biotech companies, driven by heightened investor interest in innovative therapies, especially in oncology and rare diseases. This surge is marked by an increase in partnerships and public offerings, as companies seek to leverage their unique capabilities and accelerate the development of groundbreaking treatments. Market analysts suggest that this trend is likely to continue, as the demand for novel therapies grows alongside an aging population and rising healthcare costs. The favorable funding environment is further bolstered by the success of recent IPOs, which have provided a blueprint for emerging companies to attract investment. Additionally, larger pharmaceutical firms are increasingly looking to acquire smaller biotech firms to bolster their pipelines, particularly in high-growth areas, thereby intensifying competition in the marketplace. As the landscape evolves, stakeholders should remain vigilant about the implications of these trends. The ongoing consolidation within the industry may lead to fewer players but could also foster innovation as companies combine resources and expertise. Investors are advised to monitor developments closely, as the dynamics of funding and M&A will likely shape the future of the pharmaceutical industry, influencing stock valuations and strategic positioning across the sector.

Index membership

• S&P 500 · Health Care

Related Health Care stocks

• AAgilent Technologies
• ABBVAbbVie
• ABTAbbott Laboratories
• ALGNAlign Technology
• AMGNAmgen
• BAXBaxter International
• BDXBecton Dickinson
• BMYBristol Myers Squibb